95,327 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans bought a new stake in Cabaletta Bio, Inc. (NASDAQ:CABA) in the 4th quarter, HoldingsChannel reports. The firm bought 95,327 shares of the company’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CABA. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cabaletta Bio during the 3rd quarter valued at about $32,000. Point72 DIFC Ltd purchased a new position in Cabaletta Bio during the third quarter worth about $33,000. Charles Schwab Investment Management Inc. boosted its holdings in Cabaletta Bio by 6.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 125,845 shares of the company’s stock valued at $594,000 after purchasing an additional 7,518 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Cabaletta Bio by 23.3% in the 4th quarter. SG Americas Securities LLC now owns 43,259 shares of the company’s stock valued at $98,000 after buying an additional 8,161 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of Cabaletta Bio during the 3rd quarter worth approximately $67,000.

Cabaletta Bio Price Performance

NASDAQ CABA opened at $1.11 on Friday. The company has a market cap of $56.32 million, a P/E ratio of -0.52 and a beta of 2.44. Cabaletta Bio, Inc. has a 1-year low of $1.08 and a 1-year high of $19.04. The stock has a 50-day moving average of $1.98 and a two-hundred day moving average of $2.89.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.65) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.65). On average, analysts anticipate that Cabaletta Bio, Inc. will post -2.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CABA. Guggenheim reiterated a “buy” rating and issued a $23.00 price objective on shares of Cabaletta Bio in a report on Tuesday. Evercore ISI lowered Cabaletta Bio from an “outperform” rating to an “inline” rating and decreased their price target for the company from $15.00 to $6.00 in a research note on Friday, December 20th. Wells Fargo & Company cut their price objective on Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday. UBS Group decreased their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Tuesday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cabaletta Bio presently has an average rating of “Buy” and an average target price of $21.00.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.